Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference...

Area of Science:

• Toxicological Pathology
• Cardiovascular Safety Pharmacology
• Drug Development Risk Assessment

Background:

• Cardiovascular adverse effects are a leading cause of drug attrition.
• A joint meeting of the British Society of Toxicological Pathology (BSTP) and the Safety Pharmacology Society (SPS) addressed this critical issue.
• The meeting focused on improving understanding and awareness of cardiovascular risk assessment in drug safety.

Framework:

• Fostering inter-disciplinary collaboration between toxicological pathology and safety pharmacology.
• Integrating functional and pathological assessments of drug-induced cardiovascular effects.
• Enhancing the translation of nonclinical safety data to human risk.

Implementation:

• Presentations covered electrophysiological and hemodynamic changes.
• Discussions included both purely functional and combined functional-pathological adverse effects.
• Focus on nonclinical safety data with human translation where available.

Implications:

• Improved cardiovascular risk assessment strategies in drug development.
• Enhanced understanding of drug-induced cardiovascular toxicity.
• Increased awareness and adoption of new technologies for safety evaluation.